[Management of targeted molecular therapies toxicities in thoracic cancerology].
Targeted molecular therapies, mainly enzyme inhibitors and humanized antibodies, are being widely developed, especially in the area of lung cancer. Though often considered to be better tolerated than conventional cytotoxic chemotherapies, targeted molecular therapies induce specific toxicities that may have detrimental effects on the quality of life. We sum up various toxicities from targeted treatment available for lung cancer in France with the aim of improving their prevention, diagnosis and management.
Rajpar
S
S
Département de Médecine, Institut Gustave-Roussy, 39 Rue Camille-Desmoulins, 94800 Villejuif, France.
Osio
A
A
Besse
B
B
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000633:toxicity*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000633:toxicity*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000633:toxicity*; D000068258:Bevacizumab; D016503:Drug Delivery Systems; D000069347:Erlotinib Hydrochloride; D005602:France; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000523:psychology; D010166:Palliative Care / Q000379:methods*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000633:toxicity*; D011788:Quality of Life / Q000523:psychology; D011799:Quinazolines / Q000008:administration & dosage / Q000633:toxicity*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride